Party pills and drug-drug interactions

New Zealand Medical Journal

Volumn 122, Issue 1293, 2009, Pages 16-25

  Murphy, Meghan ^a   Antia, Ushtana ^a   Chang, Hsin Yao ^a   Han, Jae Young ^a   Ibrahim, Abir ^a   Tingle, Malcolm ^a   Russell, Bruce ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1 BENZYLPIPERAZINE DERIVATIVE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; ETHINYLESTRADIOL; OMEPRAZOLE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MALE;

EID: 67649949518     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wilkins C, Girling M, Sweetsur P, Huckle T. Legal party pill use in New Zealand: Prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP). Auckland: Centre for Social and Health Outcomes Research and Evaluation (SHORE), Massey University; 2006.
2. Baumann MH, Clark RD, Budzynski AG, et al. (). N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology. 2005;30(3):550-60.
3. Staack RF, Paul L., Springer D, et al. Cytochrome P450 dependent metabolism of the new designer drug 1-(3trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochemical Pharmacology. 2004;67(2), 235-44.
4. Sternbach H. The Serotonin Syndrome. American Journal of Psychiatry, 1991;148:705-13.
5. Andersson T, Miners JO, Veronese ME, Birkett DJ. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology. 1994;37(6):597-604.
6. Prueksaritanont T, Gorham LM, Ma B, et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metabolism & Disposition. 1997;25(10):1191-9.
7. Gee P, Richardson S, Woltersdorf W, Moore G. Toxic effects of BZP-based herbal party pills in humans: A prospective study in Christchurch, New Zealand. New Zealand Medical Journal. 2005;118(1227). http://www.nzmj.com/journal/118-1227/1784
8. Lee CA, Manyike PT, Thummel KE, et al. Mechanism of cytochrome P450 activation by caffeine and 7,8-benzoflavone in rat liver microsomes. Drug Metabolism and Disposition. 1997;25(10):1150-6.
9. Fuhr U, Wolff T, Harder S, et al. Quinolone inhibition of cytpchrome P-450-dependent caffeine metabolism in human liver microsomes. Drug Metabolism and Disposition. 1990;18(6):1005-10.
10. Kerlan V, Dreano Y, Bercovici JP, et al. Nature of cytochromes P450 involved in the 2-/4-hydroxylations of estradiol in human liver microsomes. Biochemical Pharmacology. 1992;44(9):1745-56.
11. Shu Y, Wang LS, Xu ZH, et al. 5-hydroxylation of omeprazole by human liver microsome fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity. Journal of Pharmacology and Experimental Therapeutics. 2000;295(2):844-51.
12. Staack RF, Fritschi G, Maurer HH. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences. 2002a;773(1):35-46.
13. Meyer UA. Overview of enzymes of drug metabolism. Journal of Pharmacokinetics & Biopharmaceutics. 1996;24(5):449-59.
14. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. British Journal of Clinical Pharmacology. 1992;33(5):521-3.
15. Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteinedebrisoquin oxidation polymorphism, in the metabolism of imipramine. Clinical Pharmacology & Therapeutics. 1991;49(6):609-17.
16. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine. 2000;79(4):201-9.
17. Balmelli C, Kupferschmidt H, Rentsch K, Schneeman M. Fatal brain edema after ingestion of ecstasy and benzylpiperazine [article in German]. Dtsch Med Wochenschr. 2001;126(28-29):809-11.
18. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Alimentary Pharmacology & Therapeutics. 1994;8 Suppl 1:33-8.
19. Mandel HG. Update on caffeine consumption, disposition and action. Food & Chemical Toxicology. 2002;40(9):1231-4.
20. Fuhr U, Doehmer J, Battula N, et al. Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochemical Pharmacology. 1992;43(2):225-35.
21. Leson CL, McGuigan MA, Bryson SM. Caffeine overdose in an adolescent male. Journal of Toxicology - Clinical Toxicology, 1988;26(5-6):407-15.
22. Ballesteros S, Martinez MA, Ballesteros MA, et al. A severe case of olanzapine overdose with analytical data. Clinical Toxicology: The Official Journal of the American Academy of Clinical Toxicology & European Association of Poisons Centres & Clinical Toxicologists, 2007;45(4):412-5.
23. Sanchez-Ojanguren J, Escudero D, Zapata A. [Occlusion of the right common carotid artery due to oral estrogen overdose]. Revista de Neurologia, 1998;27(158):604-6.
24. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochemical Pharmacology, 1994;47(11):1969-79.
25. Delcker A, Wilhelm H, Timmann D, Diener HC. Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. European Neuropsychopharmacology, 1997;7(3):213-8.
26. Gee P, Fountain J. Party on? BZP party pills in New Zealand. New Zealand Medical Journal. 2007;120(1249). http://www.nzmj.com/journal/121-1283/ 3289
27. Antia U. Metabolism of Party Pill drug - TFMPP. In; 2007; ASCEPT NZ Scientific Meeting, Auckland, New Zealand; 2007.